Aims: We investigated the relationship between elevated intraocular pressure (IOP) and changes in global and peripapillary sector retinal nerve fiber layer (RNFL) thickness around the optic nerve head (ONH) in the laser-induced ocular hypertension monkey model. Methods: To induce high IOP, green laser photocoagulation burns were applied around the trabecular meshwork of 1 eye from each of 12 cynomolgus monkeys. The animals had been acclimated to IOP measurement under conscious conditions for more than 2 months, and IOP was chronologically measured. RNFL thickness was measured for 6 peripapillary sectors and global area using spectral-domain optical coherence tomography. Results: After model induction, marked IOP elevation and enlarged optic disk cupping were observed. Thinning of the RNFL associated with elevated IOP was observed around the ONH from 6 until 9 weeks after laser treatment, and the degree of reduction in RNFL thickness varied between the peripapillary sectors. Correlations between cumulative IOP elevation and RNFL thickness reduction were statistically significant for the temporal-superior (p = 0.024), nasal-inferior (p = 0.044), and temporal (p = 0.049) sectors, and global RNFL (p = 0.018). Conclusions: These results suggest that this model reflected the pathology of clinical glaucoma in terms of the specific pattern of RNFL thinning around the ONH.

1.
Quigley HA: Open-angle glaucoma. N Engl J Med 1993;328:1097-1106.
2.
Weinreb RN, Khaw PT: Primary open-angle glaucoma. Lancet 2004;363:1711-1720.
3.
Quigley HA, Miller NR, George T: Clinical evaluation of nerve fiber layer atrophy as an indicator of glaucomatous optic nerve damage. Arch Ophthalmol 1980;98:1564-1571.
4.
Sommer A, Miller NR, Pollack I, Maumenee AE, George T: The nerve fiber layer in the diagnosis of glaucoma. Arch Ophthalmol 1977;95:2149-2156.
5.
Weinreb RN, Shakiba S, Sample PA, Shahrokni S, van Horn S, Garden VS, Asawaphureekorn S, Zangwill L: Association between quantitative nerve fiber layer measurement and visual field loss in glaucoma. Am J Ophthalmol 1995;120:732-738.
6.
Bogunovic H, Kwon YH, Rashid A, Lee K, Critser DB, Garvin MK, Sonka M, Abramoff MD: Relationships of retinal structure and Humphrey 24-2 visual field thresholds in patients with glaucoma. Invest Ophthalmol Vis Sci 2015;56:259-271.
7.
Mwanza JC, Warren JL, Budenz DL; Ganglion Cell Analysis Study Group: Combining spectral domain optical coherence tomography structural parameters for the diagnosis of glaucoma with early visual field loss. Invest Ophthalmol Vis Sci 2013;54:8393-8400.
8.
Miki A, Medeiros FA, Weinreb RN, Jain S, He F, Sharpsten L, Khachatryan N, Hammel N, Liebmann JM, Girkin CA, Sample PA, Zangwill LM: Rates of retinal nerve fiber layer thinning in glaucoma suspect eyes. Ophthalmology 2014;121:1350-1358.
9.
Gaasterland D, Kupfer C: Experimental glaucoma in the rhesus monkey. Invest Ophthalmol 1974;13:455-457.
10.
Bouhenni RA, Dunmire J, Sewell A, Edward DP: Animal models of glaucoma. J Biomed Biotechnol 2012;2012:692609.
11.
Hayreh SS, Pe'er J, Zimmerman MB: Morphologic changes in chronic high-pressure experimental glaucoma in rhesus monkeys. J Glaucoma 1999;8:56-71.
12.
Shimazawa M, Tomita G, Taniguchi T, Sasaoka M, Hara H, Kitazawa Y, Araie M: Morphometric evaluation of changes with time in optic disc structure and thickness of retinal nerve fibre layer in chronic ocular hypertensive monkeys. Exp Eye Res 2006;82:427-440.
13.
Harwerth RS, Vilupuru AS, Rangaswamy NV, Smith EL 3rd: The relationship between nerve fiber layer and perimetry measurements. Invest Ophthalmol Vis Sci 2007;48:763-773.
14.
Sasaoka M, Nakamura K, Shimazawa M, Ito Y, Araie M, Hara H: Changes in visual fields and lateral geniculate nucleus in monkey laser-induced high intraocular pressure model. Exp Eye Res 2008;86:770-782.
15.
Schuman JS, Pedut-Kloizman T, Pakter H, Wang N, Guedes V, Huang L, Pieroth L, Scott W, Hee MR, Fujimoto JG, Ishikawa H, Bilonick RA, Kagemann L, Wollstein G: Optical coherence tomography and histologic measurements of nerve fiber layer thickness in normal and glaucomatous monkey eyes. Invest Ophthalmol Vis Sci 2007;48:3645-3654.
16.
He L, Yang H, Gardiner SK, Williams G, Hardin C, Strouthidis NG, Fortune B, Burgoyne CF: Longitudinal detection of optic nerve head changes by spectral domain optical coherence tomography in early experimental glaucoma. Invest Ophthalmol Vis Sci 2014;55:574-586.
17.
Patel NB, Sullivan-Mee M, Harwerth RS: The relationship between retinal nerve fiber layer thickness and optic nerve head neuroretinal rim tissue in glaucoma. Invest Ophthalmol Vis Sci 2014;55:6802-6816.
18.
Strouthidis NG, Fortune B, Yang H, Sigal IA, Burgoyne CF: Longitudinal change detected by spectral domain optical coherence tomography in the optic nerve head and peripapillary retina in experimental glaucoma. Invest Ophthalmol Vis Sci 2011;52:1206-1219.
19.
Luo X, Patel NB, Harwerth RS, Frishman LJ: Loss of the low-frequency component of the global-flash multifocal electroretinogram in primate eyes with experimental glaucoma. Invest Ophthalmol Vis Sci 2011;52:3792-3804.
20.
Fortune B, Burgoyne CF, Cull GA, Reynaud J, Wang L: Structural and functional abnormalities of retinal ganglion cells measured in vivo at the onset of optic nerve head surface change in experimental glaucoma. Invest Ophthalmol Vis Sci 2012;53:3939-3950.
21.
Luo X, Patel NB, Rajagopalan LP, Harwerth RS, Frishman LJ: Relation between macular retinal ganglion cell/inner plexiform layer thickness and multifocal electroretinogram measures in experimental glaucoma. Invest Ophthalmol Vis Sci 2014;55:4512-4524.
22.
Mok KH, Lee VW, So KF: Retinal nerve fiber layer measurement by optical coherence tomography in glaucoma suspects with short-wavelength perimetry abnormalities. J Glaucoma 2003;12:45-49.
23.
Caprioli J, Nouri-Mahdavi K, Law SK, Badala F: Optic disc imaging in perimetrically normal eyes of glaucoma patients with unilateral field loss. Trans Am Ophthalmol Soc 2006;104:202-211.
24.
Krupin T, Liebmann JM, Greenfield DS, Ritch R, Gardiner S; Low-Pressure Glaucoma Study Group: A randomized trial of brimonidine versus timolol in preserving visual function: results from the Low-Pressure Glaucoma Treatment Study. Am J Ophthalmol 2011;151:671-681.
25.
Garway-Heath DF, Crabb DP, Bunce C, Lascaratos G, Amalfitano F, Anand N, Azuara-Blanco A, Bourne RR, Broadway DC, Cunliffe IA, Diamond JP, Fraser SG, Ho TA, Martin KR, McNaught AI, Negi A, Patel K, Russell RA, Shah A, Spry PG, Suzuki K, White ET, Wormald RP, Xing W, Zeyen TG: Latanoprost for open-angle glaucoma (UKGTS): a randomised, multicentre, placebo-controlled trial. Lancet 2015;385:1295-1304.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.